Context Therapeutics Analyst Ratings
Context Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/01/2023 | 323.73% | HC Wainwright & Co. | → $5 | Upgrades | Neutral → Buy |
| 09/11/2023 | 238.98% | Maxim Group | → $4 | Initiates Coverage On | → Buy |
| 06/06/2023 | — | HC Wainwright & Co. | Reiterates | → Neutral | |
| 03/23/2023 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 02/07/2023 | 238.98% | HC Wainwright & Co. | → $4 | Reiterates | → Buy |
| 02/02/2022 | 408.47% | HC Wainwright & Co. | → $6 | Initiates Coverage On | → Buy |
| 01/24/2022 | 747.46% | ThinkEquity | → $10 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年11月1日 | 323.73% | HC Wainwright公司 | →$5 | 升級 | 中性→購買 |
| 09/11/2023 | 238.98% | Maxim集團 | →$4 | 開始承保 | →購買 |
| 06/06/2023 | - | HC Wainwright公司 | 重申 | →中性 | |
| 03/23/2023 | - | HC Wainwright公司 | 評級下調 | 購買→中性 | |
| 02/07/2023 | 238.98% | HC Wainwright公司 | →$4 | 重申 | →購買 |
| 02/02/2022 | 408.47% | HC Wainwright公司 | →$6 | 開始承保 | →購買 |
| 01/24/2022 | 747.46% | ThinkEquity | →$10 | 開始承保 | →購買 |
What is the target price for Context Therapeutics (CNTX)?
Context Treeutics(CNTX)的目標價格是多少？
The latest price target for Context Therapeutics (NASDAQ: CNTX) was reported by HC Wainwright & Co. on November 1, 2023. The analyst firm set a price target for $5.00 expecting CNTX to rise to within 12 months (a possible 323.73% upside). 5 analyst firms have reported ratings in the last year.
Context Treateutics(納斯達克：CNTX)的最新目標價是由HC Wainwright&Co.於2023年11月1日報道的。這家分析公司將目標價定為5美元，預計CNTX將在12個月內上漲(可能上漲323.73%)。去年有5家分析公司公佈了評級。
What is the most recent analyst rating for Context Therapeutics (CNTX)?
Context Treeutics(CNTX)的最新分析師評級是什麼？
The latest analyst rating for Context Therapeutics (NASDAQ: CNTX) was provided by HC Wainwright & Co., and Context Therapeutics upgraded their buy rating.
上下文治療公司(納斯達克代碼：CNTX)的最新分析師評級由HC Wainwright&Co.提供，上下文治療公司上調了買入評級。
When is the next analyst rating going to be posted or updated for Context Therapeutics (CNTX)?
Context Treeutics(CNTX)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Context Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Context Therapeutics was filed on November 1, 2023 so you should expect the next rating to be made available sometime around November 1, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與Context Treeutics的高管和客戶交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Context治療公司的上一次評級是在2023年11月1日提交的，所以你應該預計下一次評級將在2024年11月1日左右的某個時候提供。
Is the Analyst Rating Context Therapeutics (CNTX) correct?
分析師對Context Treeutics(CNTX)的評級正確嗎？
While ratings are subjective and will change, the latest Context Therapeutics (CNTX) rating was a upgraded with a price target of $0.00 to $5.00. The current price Context Therapeutics (CNTX) is trading at is $1.18, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的上下文治療(CNTX)評級被上調，目標價從0.00美元到5.00美元。目前上下文治療公司(CNTX)的交易價格為1.18美元，在分析師的預測範圍內。